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n	 IntROdUctIOn
The term biomarker comes from “bio-logical markers”, that the US National 
Institutes of Health (NIH) Biomarkers and 
Surrogate Endpoint Working Group de-
fines “as objective parameters that can be 
measured and evaluated as an indicator of 
biological processes, pathogenic processes 
or pharmacological responses to therapeu-
tic intervention” (1). 
In the pathogenic processes, biomarkers 
may serve as surrogate endpoints for diag-
nosis, prognosis, disease activity, therapeu-
tic response and outcome of the disease. In 
the last ten years, with the new and now 
consolidated concepts of “early diagnosis” 
(2-5) and “treat to target” (6, 7) a huge ef-
fort has been made to identify useful tools 
to establish early diagnosis, prognosis and 
therapeutic response in rheumatoid arthri-
tis (RA) (8, 9). 
For this, a great endeavour has been made 
for the identification of serological, clini-
cal and instrumental parameters, helpful 
for identify patients at risk of developing 
persistent and aggressive disease, requir-
ing early and aggressive therapeutic inter-
vention. Among these parameters, acute 
phase reactants(10), rheumatoid factor 
(RF) and its isotypes, anti-citrullinated 
peptide antibodies (ACPA) (11-18) , sim-
ple clinical index as the number of swol-
len joints and composite index as the dis-
ease activity score (DAS) (19), the pres-
ence of ultrasonographic power doppler 
despite clinical remission of the disease, 
the bone oedema on MR imaging and the 
erosions in MR and plain radiographs (20-
26), have been identify in RA as biomark-
ers of disease activity or prognostic fac-
tors and currently used in the evaluation 
of RA patients.
Unfortunately, in Psoriatic Arthritis 
(PsA), traditional methods in evaluation 
of disease assessment and research for 
biological markers, have not kept pace 
with the accelerated development of the 
concept of early diagnosis and prognostic 
stratification, the appearance of the new 
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SUMMARY
In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, 
therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools 
to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In pso-
riatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have 
sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heteroge-
neous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis 
and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the 
articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised 
the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological 
biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify 
progressive disease suitable for a more aggressive treatment.
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therapeutic options and also with the new 
PsA classification and the re-evaluation of 
their different clinical subsets (27) (from 
the Moll and Wright to the CASPAR clas-
sification) (28-30).
So, in PsA, serological biomarkers, such 
as the domains assessing clinical outcome 
(for example swollen and tender joints, vis-
ual analogical scale (VAS) for patient and 
physician global assessment, VAS for pain, 
Health Assessment Questionnaire (HAQ)), 
have been frequently borrowed from RA 
because of the similarities between the dis-
eases and the good response to the same 
therapeutic approach with biological drugs 
(31, 32). Nevertheless, this “copy-past” ap-
proach from RA to PsA have sometimes 
lead to inappropriate choices of biomarkers 
and subsequently to incorrect conclusions.
Compared with RA, PsA is a more complex 
disease from both clinical and pathogenetic 
point of view and the use of RA biomarkers 
may be reductive and make diagnosis and 
prognosis difficult.
Recently, the increased data demonstrat-
ing the different pathogenesis and disease 
process in PsA (33) and RA (34), rises 
new attention among PsA researchers in 
the identification and validation of specific 
biomarkers. The Group for Research and 
Assessment of Psoriasis and Psoriatic Ar-
thritis (GRAPPA) identified two key areas 
for biomarker development in psoriasis and 
PsA:
1. articular disease diagnosis in patients 
with psoriasis;
2. joint damage in PsA (35).
With particular attention on the second key 
area, in the 2008 GRAPPA meeting held in 
Leeds (UK), a special working group for 
the development of soluble and synovial 
tissue biomarkers in PsA, under the um-
brella of the Outcome Measures in Rheu-
matology (OMERACT), began to develop 
validation tools reflecting the variety of 
different process and phisiopathological 
mechanisms in PsA (37).
The aim of this review is to summarize the 
actually available biomarkers for PsA with 
a particular attention on those that may 
help clinicians in the prognostic stratifica-
tion of PsA patients.
n	 SERUM BIOMARKERS
Erythrocyte sedimentation rate (ESR) and 
C- reactive protein (CRP)
Recently, Chandran and co-workers show 
that highly sensitive CRP (hs-CRP) levels 
are higher in PsA patients compared with 
those observed in patients with psoriasis 
alone and that it may be a biomarker of 
PsA because indicates additional inflam-
mation (36). Nevertheless, hs-CRP is not 
available for routine analysis and classical 
acute phase reactant, such as ESR and CRP, 
are generally used. However, ESR and 
CRP are reported as normal in up to 50% 
of patients with PsA despite clinically ac-
tive disease; their contribute for diagnosis 
is very limited while they may have a role 
in the assessment of disease activity (37, 
38). More than 20 years ago, Gladmann 
and co-workers found that acute phase re-
actants correlate with a higher number of 
involved joints and represent a negative 
prognostic predictor, especially in the pe-
ripheral subset of PsA with respect to the 
axial and enthesitic form (38). In a recent 
study, CRP has been evaluated as a marker 
for response to therapeutic intervention 
with tumor necrosis factor-alpha (TNFalfa) 
antagonists in patients with PsA. Moreo-
ver, higher levels of CRP were found to 
be a good predictor of response and along 
with other clinical features (lower HAQ-DI 
score, polyarthritis) increased the chance 
of achieving clinical improvements with 
anti-TNFalfa drugs (39).
Cytokines
Significantly higher serum levels of IL-6, 
IL-10, soluble receptor of IL-2 (sIL-2R) 
and IL-1 receptor antagonists (IL-1ra) were 
found in patients with PsA in comparison 
with healthy volunteers (40). In previous 
studies, a correlation between IL-6 levels 
and the number of painful and swollen 
joints was demonstrated (41); moreover, 
serum IL-6 appears to be a better marker of 
inflammation than the classical acute phase 
reactants (ESR and CRP) and correlates 
with the number of affected joints (42) in 
patients with psoriasis and inflammatory 
joint disease. More recently, Elkayam O et 
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al. did not found any correlation between 
IL6 levels and severity of joint involve-
ment. This discrepancy may be due to dif-
ferences in the patients’ population (pol-
yarticular vs oligoarticular involvement) 
suggesting that this association may exists 
only in polyarticular arthritis (42). Howev-
er, studies of markers of inflammation both 
in healthy subjects and in patients with RA 
have shown a statistically significant circa-
dian variation in levels of IL-6, suggesting 
that it would be a less robust marker than 
those without diurnal variation (43).
In the same study by Elkayam and co-
workers, no association was found between 
levels of IL-10 and sIL-2R and clinical pa-
rameters, whereas levels of IL-1ra seem 
to correlate with the number of tender and 
swollen joints in patients with peripheral 
form. No significant association was found 
between IL-1ra serum levels and clinical 
lumbar involvement, suggesting that IL-
1ra, as well as IL-6, may be useful in the 
future as serum biomarkers of disease ac-
tivity in Psa, especially in the peripheral 
form (42).
Autoantibodies
Rheumatoid factor (RF) is the longest-
standing autoantibody test to distinguish 
RA from other forms of arthritis and in-
cluded in the recentlu published 2010 
classification criteria for RA (4), replac-
ing the 1987 American College of Rheu-
matology (ACR) criteria (44). It has been 
documented as a useful marker for the 
diagnosis and the prognosis of RA, with 
a sensitivity of 68-81% and a specificity 
of 60-85%, until the identification of anti 
cyclic cytrullinated peptides antibodies 
(ACPA), showing a higher specificity (90-
98%) and comparable sensitivity (45). 
Although RF facilitated the classification 
of polyarthritis, the differential diagnosis 
between RA and PsA is a complex clini-
cal work and the utility of autoantibodies 
is frequently considered marginal. For ex-
ample, it is well known that in adult peo-
ple of Northern Italy, RF may be related to 
HCV infection, which occurs in 5 to 10% 
of the general population, not associated 
with arthritis (46). This may lead to an in-
creased rate of RF posotivity in otherwise 
seronegative arthritis (47). 
Despite in the Moll and Wright classifica-
tion criteria for PsA (30) RF is an exclu-
sion criteria and in the new CASPAR clas-
sification a negative RF is considered as a 
minor criteria for the diagnosis (31), RF 
was found in a variable percentage of PsA, 
ranging between 2% and 16,5% in patients 
with psoriasis and inflammatory arthritis 
(48-51). In all of the studies no significant 
correlation was found between RF positiv-
ity and erosive disease or number of swol-
len and/or involved joints. 
More than RF, ACPA are considered highly 
specific markers of RA, with a predictive 
value for subsequent structural damage 
(52, 53), persistence of synovitis (54, 55), 
the need for intensive treatment (56), de-
cline of function in the course of disease 
(57) and premature death (58). In unidiffer-
entiated Polyarthritis (UPA), several stud-
ies describe high predictive value of ACPA 
positivity at baseline with respect to the de-
velopment of overt RA at 1-year follow-up 
(54, 55, 59, 60). Moreover, the presence of 
ACPA has been linked to development of 
RA even in healthy populations (61).
Despite their high specificity for RA, 
ACPA have also reported in other condi-
tions such systemic lupus erythematosus 
(SLE) (62, 63) , Sjögren syndrome (64), 
systemic sclerosis (65) and others connec-
tive tissue disease (66) and in the major-
ity of cases ACPA were associated with 
erosive joint involvement (64, 65, 67, 68) 
suggesting that the risk of deforming and 
erosive arthritis is closely related to ACPA 
positivity. Moreover, ACPA have been 
observed also in psoriatic arthritis, with a 
proportion ranging from 5 to 16% (51, 53, 
67, 68). In PsA, as in RA, ACPA seems to 
be useful in detecting those patients with 
a higher number of involved and swollen 
joints (51, 59) and with an increased risk 
of erosion, requiring early DMARD treat-
ment with conventional drugs or biological 
agents (53). 
It is possible that RA with RF or ACPA 
positivity may occur in patients with pso-
riasis, even if the reported association be-
tween ACPA and erosive arthritis in more 
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then one disease, different from RA, re-
quire a more complex explanation. Inter-
esting, in the study by our group, enthesi-
tis, dactylitis and axial or DIP involvement 
was similar in the ACPA positive patients 
compared to the ACPA negative group, 
meaning that ACPA are not restricted to 
those patients with a clear-cut clinical 
picture of RA, as they may be present in 
patients with features usually regarded as 
typical of PsA and seronegative spondylo-
arthropathies.
Circulating mediators of cartilage and 
bone remodelling
Cartilage destruction and remodeling are 
features of inflammatory arthritis. The 
products of cartilage synthesis and destruc-
tion are released into the serum during this 
process and may also serve as biomarkers 
(38). Whereas RA primarily results in bone 
and cartilage resorption, PsA combines de-
structive elements with anabolic bone re-
sponses and cartilage apposition (70).
Osteoprotegerin (OPG) is a cytokine and 
a potential marker of periostitis and new 
bone formation which is a characteristic 
feature of PsA that differentiated it from 
other inflammatory arthritis. Recent stud-
ies have shown that an increased level of 
OPG may be used as a marker of PsA in 
patients with psoriasis and may indicate the 
presence of new bone formation (38). 
Another informative marker of cartilage 
remodeling is the ratio between C-propep-
tide of type II collagen (CPII) and collagen 
fragment neoepitopes (C2C), that reflects 
the balance between type II collagen syn-
thesis and degradation. This parameter is 
an independent biomarker for PsA and may 
indicate new bone formation. Also, matrix 
metalloproteinase-3 (MMP-3), an enzyme 
with a role in the destruction of cartilage 
and bone in rheumatic diseases character-
ized by synovitis, has been shown to be as-
sociated with PsA (38). However, these bi-
omarkers may be useful to identify patients 
with psoriasis at increased risk of having 
PsA, helping in early diagnosis, but no as-
sociation was found with disease activity 
and prognosis of PsA.
Instead, the extent of bone loss at the pe-
ripheral joints is associated with elevated 
circulating macrophage-colony stimulating 
factor (M-CSF) and receptor activator of 
nuclear factor kappa-B ligand (RANKL) 
concentrations in serum samples from PsA 
patients. Serum levels of M-CSF in par-
ticular are elevated in patients with erosive 
arthritis and strongly correlate with sever-
ity of peripheral erosive disease. Therefore, 
markers such as M-CSF and RANKL may 
have a role to identify patients in whom 
progressive or accelerated joint damage 
will develop (71).
Furthermore, cartilage oligomeric matrix 
protein (COMP), a glycoprotein expressed 
in cartilage, tendons, meniscus and syno-
vial membrane, can be used as a param-
eter for the extent of cartilage destruction 
because its release pattern in serum may 
reflect cartilage turnover. Serum levels of 
COMP have been demonstrated to be an 
indicator for disease activity in patients 
with PsA, because those with active dis-
ease showed significantly elevated COMP 
serum levels compared to the patients with 
low disease activity. Indeed, this parameter 
correlates significantly with acute-phase 
reactants (CRP) and the number of swollen 
joints (72).
Clinical biomarkers
PsA is classified as a spondyloarthropathy 
because of the presence of axial involve-
ment in up to 40% of patients with a charac-
teristic asymmetrical distribution (73, 74). 
Nevertheless, prognostic factors have not 
been extensively studied for the axial form 
of PsA and it is not clear from the literature 
if axial involvement imply a worse progno-
sis of PsA patients (75, 76). Moreover, it 
is frequently difficult to establish with cer-
tainty the presence of inflammatory back 
pain (IBP) in patients with PsA (77) who 
generally have less pain than patients with 
ankylosing spondylitis (AS) (78).
The only demonstrated clinical predictor 
of aggressive PsA is the involvement of 
the peripheral joints. Cohort studies have 
suggested a link between inflammation 
and joint damage, showing that swollen 
joints are a predictor of future increase in 
the clinically damaged joint count (79, 80) 
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and of radiologic progression (53, 81). Par-
ticularly, in the study of Gladmann DD et 
al., polyarticular onset of the disease, with 
more than five involved joints and a high 
medication level at presentation to the clin-
ic, predicted the progression of the disease, 
with an increased joint damage (40). In 
another study, the polyarticular disease at 
onset predicted not only the development 
of clinical deformities but also an erosive 
disease (82). More recently, Simon P et al 
concluded that also an increasing number 
of swollen joints, during a 12-month period 
of follow-up, heralds progression of radio-
logical damage in PsA patients (83).
n	 IMAgIng 
Imaging studies have demonstrated the di-
rect link between inflammation and joint 
damage in RA, using a combination of ul-
trasound (US), conventional radiography 
and MRI (72, 84, 85). In PsA, such data are 
currently unavailable and the link between 
inflammation of enthesis and/or synovium 
with joint damage, is still under investiga-
tion. Nevertheless, similar to RA (86), in 
observational cohort studies in PsA radio-
logical damage was found to be predictive 
of increased mortality (87).
Recently, US and MRI have been validated 
as sensitive techniques in the early diagno-
sis of synovitis (88) and enthesitis (89) in 
PsA, but no clear data are available on their 
prognostic value.
Although the interest in this field is grow-
ing, US and MRI studies of PsA are fewer 
than those in RA and further studies are 
needed to clarify the relevance of the typi-
cal aspects of extracapsular enhancement 
and enthesitis of PsA. At now, these char-
acteristics seems to be more relevant to 
underline the “enthesis-related origin” of 
PsA proposed in contrast to the primarily 
synovial inflammation of RA (90, 91), than 
useful to identify prognostic aspect of the 
disease. 
Moreover, bone erosions in PsA are prob-
ably less frequent and progressive than in 
RA and bone oedema is unlikely to pre-
dict the appearance of erosions in patients 
with PsA (92). So, while many GRAPPA 
members expressed considerable support 
for the advantages provided by MRI as an 
outcome measure in PsA, since no scoring 
technique has yet been validated, the inclu-
sion of MRI as a primary outcome imaging 
tool may be premature. Thus, plain radio-
graphs of hands and feet were considered 
an essential primary radiologic outcome 
measure for progression of erosions, with 
MRI sub-study strongly recommended, 
where feasible.
An early use of MRI has recently described 
also for diagnostic and prognostic stratifi-
cation of patients with axial involvement in 
which the clinical symptoms of low-back 
pain and the typical radiographic aspects 
may be observed only when the disease is 
still consolidated (79). 
n	 OthERS BIOMARKERS: 
 nEw pROSpEctIvE  
 fROM thE gEnEtIc  
 tO cEllUlAR And  
 hIStOlOgIcAl BIOMARKERS
Genetic factors are very important not only 
for psoriasis susceptibility (93, 94), but 
also in the expression of PsA, and their 
role is evident when considering the strong 
heritability of PsA (95). Nevertheless, ge-
netic association studies of PsA are limited 
by its changing articular pattern over time 
and because of each pattern of PsA may 
not be genetically distinct, considering the 
frequent overlapping between clinical sub-
groups. So, although the strong evidence 
for the genetic basis of PsA (96) only a few 
genes have been identified thus far as inde-
pendent susceptibility genes for PsA. 
At the moment genetic factors appear to be 
related with the clinical phenotype of PsA 
(axial involvement, polyarticular involve-
ment) rather than with diagnosis or prog-
nosis (97-99). 
The HLA-DR4 antigen has been reported 
to be increased in PsA with a clinical pic-
ture resembling RA and particularly in pa-
tients who developed radiological erosions 
(100, 101), but recently, Queiro-Silva at 
al. do not support the notion of the HLA-
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DR4 antigen as a marker of disease sever-
ity (102).
A positive correlation with disease activity 
was found for peripheral blood mononu-
clear cell (PBMC) gene expression of bone 
morphogenetic protein-4 (BMP-4), empha-
sizing the importance of alterations in bone 
metabolism in active PsA and identifying 
BMP-4 as a disease severityAnother mark-
er that may be relevant in the near future 
is represented by the increased number of 
circulating osteoclast precursors (OCPs) in 
blood samples from PsA patients that may 
indicate the presence of a severe erosive 
disease (104, 105).
Finally, some typical aspects of synovial 
biology of PsA, such as synovial infiltrate, 
expression of pro-inflammatory cytokines 
and adhesion molecules and dysregulated 
angiogenesis with increased vascularity, 
have been recently investigated as possible 
prognostic marker (106-110). Neverthe-
less, although much has been learned about 
the pathogenesis of PsA, much remains to 
be defined regarding the link between sy-
novial biology and different disease out-
comes. The rapid advance in ultrasound 
technology, through minimal invasive bi-
opsy, has enabled the collection of synovial 
tissue from arthritis patients (111) with a 
realistic prospect to correlate different PSA 
phenotypes, ultrasound images and cellu-
lar and molecular mechanisms of abnormal 
bone remodeling of PsA, useful to improve 
prognostic algorithms.
n	 cOnclUSIOnS
In recent years, there has been a growing 
appreciation of the potential severity of 
PsA. Whereas PsA was previously consid-
ered to be a relatively mild form of arthri-
tis, it is now clear that it can be progressive, 
destructive and deforming (82, 112-114). 
In fact, about 20% of the patients develop 
a very destructive disabling form of arthri-
tis and a recent study of early onset PsA 
showed that within two years of onset, 47% 
of patients demonstrated at least one bone 
erosion (115). Disability and quality of life 
are adversely affected in patients with PsA 
to an equivalent degree as in RA (122); so, 
remission is considered to be the ultimate 
goal of therapy in PsA like in RA (9, 33). 
Nevertheless, between the rheumatic dis-
eases, experts recognized that remission in 
PsA may be difficult to achieve and main-
tain and it has been concluded that “near 
remission” or “low disease activity” could 
be an appropriate goal, today acceptable 
for PsA (116, 117).
So, it seems crucial from a practical point 
of view, to identify prognostic factors in 
PsA tha enable clinicians to differentiate 
from the beginning the more aggressive 
form of disease and to treat it accordingly. 
At the moment, it is quite clear that pol-
yarticular onset, with more than 5 joints 
involved, high ESR at presentation, ACPA 
positivity and the presence of erosion at 
plan radiographs, identify an erosive and 
progressive arthritis, in which aggressive 
and early therapy may improve the prog-
nosis (3, 5, 7-9).
The recent update on biomarkers in PSA 
from the GRAPPA 2010 annual meeting, 
summarize the current knowledge biomar-
kers but in the same time underline that one 
important critical area is the identification 
of biomarkers of joint damage in PsA, in-
cluding both erosive change and new bone 
formation. More studies on this important 
topic are warranted in the next future.
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